Nivolumab + Chemotherapy for Mesothelioma
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently using prednisone at a dose of 10 mg or more daily, or if you have an autoimmune disease requiring treatment in the past two years.
What safety data exists for the combination of Nivolumab and chemotherapy in treating mesothelioma?
What makes the drug combination of Nivolumab, Cisplatin or Carboplatin, and Pemetrexed unique for treating mesothelioma?
This treatment is unique because it combines Nivolumab, an immunotherapy drug that helps the immune system attack cancer cells, with chemotherapy drugs Cisplatin or Carboplatin and Pemetrexed, which are already known to be effective in treating mesothelioma. The addition of Nivolumab may enhance the overall effectiveness of the treatment by boosting the body's natural defenses against cancer.14567
What data supports the effectiveness of the drug combination Nivolumab + Chemotherapy for Mesothelioma?
Who Is on the Research Team?
Michael Offin
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with resectable malignant pleural mesothelioma. Participants must have a performance status indicating they are relatively active, agree to contraception if of childbearing potential, and not be pregnant or breastfeeding. They should not have had prior chemo or immunotherapy for mesothelioma, no serious illnesses or other cancers requiring treatment, and no active hepatitis B/C or HIV.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Therapy
Participants receive two cycles of neoadjuvant therapy with nivolumab, pemetrexed, and either cisplatin or carboplatin
Surgery
Participants undergo pleurectomy/decortication
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cisplatin or Carboplatin
- Nivolumab
- Pemetrexed
- Surgery
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania